ipohypertrophy and endermotherapy® Effect of endermotherapy® treatment in insulin induced lipohypertrophy in type 1 and 2 Diabetes Mellitus patients.
- Conditions
- Insuline geinduceerde lipohypertrofie bij DM1 en DM2injection sitesInsulin injections induced Lipohypertrophy10014982
- Registration Number
- NL-OMON44781
- Lead Sponsor
- MediDerma centrum voor huid-oedeemtherapie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 20
Type 1 and type 2 Diabetes Mellitus patients F/M, bilateral insulin injections induced lipohypertrophy (LH), from 18 to 70 years, able to use different injection sites instead of the lipohypertrophic sites (in consultation with diabetes care nurse), insulin injections in lipohypertophy is not allowed during research, ability,
able to regulate blood sugar independently. Willingness to leave body weight unchanged during research.
Absence of insulin -induced bilateral LH, incompetent, under 18, over 70 years, prednison use, pregnancy, breastfeeding, malignant tumors and abnormalities in abdominal organs. Heart failure, past 6 months myocardial infarction or stroke , renal dysfunction with the MDRD is below 50. Use of anticoagulants. No alternate injection sites, not able to regulate blood sugars.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>* To determine a change in diameter and surface of treated LH after treatment<br /><br>with endermotherapy® .</p><br>
- Secondary Outcome Measures
Name Time Method